## CALR Mutation Analysis

**Ordered Items**

- CALR Mutation Analysis

### TESTS

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>CALR Mutation Detection Result</td>
<td>NEGATIVE</td>
<td>01</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Background:

No insertions or deletions were detected within the analyzed region of the calreticulin (CALR) gene.

A negative result does not entirely exclude the possibility of a clonal population carrying CALR gene mutations that are not covered by this assay. Results should be interpreted in conjunction with clinical and laboratory findings for the most accurate interpretation.

### Methodology:

Genomic DNA was isolated from the provided specimen. Polymerase chain reaction (PCR) of exon 9 of the CALR gene was performed with specific fluorescent-labeled primers, and the PCR product was analyzed by capillary gel electrophoresis to determine the size of the PCR products. This PCR assay is capable of detecting a mutant cell population with a sensitivity of 5 mutant cells per 100 normal cells.

### Methodology:

1. **Methodology:**
   - Genomic DNA was isolated from the provided specimen. Polymerase chain reaction (PCR) of exon 9 of the CALR gene was performed with specific fluorescent-labeled primers, and the PCR product was analyzed by capillary gel electrophoresis to determine the size of the PCR products. This PCR assay is capable of detecting a mutant cell population with a sensitivity of 5 mutant cells per 100 normal cells.

### Methodology:

- **Methodology:**
  - Genomic DNA was isolated from the provided specimen. Polymerase chain reaction (PCR) of exon 9 of the CALR gene was performed with specific fluorescent-labeled primers, and the PCR product was analyzed by capillary gel electrophoresis to determine the size of the PCR products. This PCR assay is capable of detecting a mutant cell population with a sensitivity of 5 mutant cells per 100 normal cells.
A negative result does not exclude the presence of a myeloproliferative disorder or other neoplastic process. This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

References:

Director Review:
Anjen Chenn, MD, PhD
Director, Molecular Oncology
LabCorp Center for Molecular Biology and Pathology
Research Triangle Park, NC 27709
1-800-533-0567

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For inquiries, the physician may contact Branch: 800-782-4344 Lab: 800-735-4087